# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-22-015743
Filing Date
2022-04-25
Accepted
2022-04-25 16:30:26
Documents
4
Period of Report
2022-06-07

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF14A | ny20002713x1_def14a.htm | DEF 14A | 1510782
2 |  | logo_biocryst2a.jpg | GRAPHIC | 30535
3 |  | ny20002713x1_pc01.jpg | GRAPHIC | 708872
4 |  | ny20002713x1_pc02.jpg | GRAPHIC | 453616
| Complete submission text file | 0001140361-22-015743.txt |  | 3154101

Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-23186 | Film No.: 22850051
SIC: 2836 Biological Products, (No Diagnostic Substances)